REC-3964 is designed to treat C. diff by selectively inhibiting the glucosyltransferase activity of toxin B produced by the bacterium in the gastrointestinal tract.

Scientists in Pennsylvania have developed an experimental mRNA-based vaccine for C. diff bacteria, which often cause ...

A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides ...

Also known as fecal microbiota transplant, or FMT, the treatment involves inoculating the colon with healthy donor stool.

Travelers' diarrhea is typically moderately to severely urgent. Learn about nonprescription medicines, antibiotics, and ...

Bacteria Striking Back Bacterial infections are much less deadly than they used to be before the introduction of antibiotics. “Before we had antibiotics, infections like scarlet fever could even lead ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS.REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic ...

Acurx Pharmaceuticals is undervalued, with promising market potential for its lead antibiotic, ibezapolstat. Find out why ...

Global Clostridium Difficile Infections Treatment MarketThe global Clostridium Difficile Infections (CDI) treatment market is ...

New study finds that a 7-day antibiotic course is just as effective as a 14-day course for treating bloodstream infections, with lower mortality rates.

Oct. 30, 2024 — An international research team has investigated how nanoplastic particles deposited in the body affect the effectiveness of antibiotics. The study showed that the plastic ...

Neosporin and other antibiotic ointments are well-known for their use on cuts that need help healing, typically on a finger or leg. But these ointments can also be applied in and around your nose ...